期刊文献+

阿托伐他汀对老年性高血压并高血压肾病的影响 被引量:7

下载PDF
导出
摘要 目的探讨阿托伐他汀对老年性高血压肾病患者肾脏的保护作用。方法64例老年性高血压肾病患者随机分为观察组32例和对照组32例,观察组在对照组治疗的基础上给予阿托伐他汀10 mg,1次/d,共12周,观察两组治疗前后及组间相关指标的变化。结果观察组患者24 h尿蛋白排泄率、血β2-微球蛋白、血清肌酐、尿素氮及C-反应蛋白均较治疗前明显下降(P<0.01或P<0.05),且与对照组治疗前后相比差异亦有显著性(P均<0.05),无严重不良反应。结论阿托伐他汀对老年性高血压肾病患者的肾脏病变有部分保护作用。
出处 《广东医学》 CAS CSCD 北大核心 2006年第5期754-755,共2页 Guangdong Medical Journal
  • 相关文献

参考文献10

  • 1ATHYROSL V G, PAPAGEORGIOUL A A, Statins and renal funcition in patients with diabetes mellitus [J]. Curr Med Res Opin,2003, 19(7):615 - 617.
  • 2RAVID M, BROSH D, RAVID- SAFRAN D, et al. Risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels,mean blood pressure, and hyperglycemia [J]. Arch Intern Med, 1998,158(9) :998 - 1004.
  • 3JANDELETT - DAHM K, CAO Z, COX A T, et al. Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy [J].Kiney Int Suppl, 1999,56(s71): 831 - 36.
  • 4于军,薛成相,李洪田,陈万强,汤洪.老年高血压病患者高脉压与靶器官损害[J].高血压杂志,2003,11(4):319-322. 被引量:30
  • 5MANN S J. Isolated systolic hypertension[J]. Medicographia, 1998,20(1):3.
  • 6KAPLAN N M. The CARE Study: a postmarketing evaluation of ramipril in 11 100 patients. The Clinical Altace Real - World Efficacy(CARE) Investigators[J]. Clin Ther, 1996, 18(4) :658 - 670.
  • 7ATHYROS V G, MIKHAILIDIS D P, PAPAGEORGION A A, et al,The effect of statins versus untreated dyslipidaemia on renal funcyion in patients with voronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study[J]. J Clin Pathol, 2004,57:728- 734.
  • 8MOORE R. Therapeutic considerations for the use of stalin therapy in chronic renal disease[J]. Nephron Clin Pract,2003,95:107- 115.
  • 9LI J J. Silent myocardial ischemia may be related to inflammatory response[J]. Med Hypotheses,2004,62:252 - 256.
  • 10LI J J. Rapid effects on lipid profile and C - reactive protein by simvastatin in patients with hypercholesterolemia[J]. Clin Cardiol,2003,26:472-476.

二级参考文献8

  • 1Alderman MH. A new model of risk: Implication of increasing pulse pressure and systolic blood pressure on cardiovascular disease[J] .J Hypertens, 1999,17(suppl 5) :S25 - S28.
  • 2Lderman MH.Distribution and determinants of cardiovascular events during 20 years of successful antihypertensive treatment[J].J hypertens, 1998,16:761 - 769.
  • 3Menotti A, Puddu PE, Lanti M.Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study[ J ]. European Heart Journal, 2000, 21 ( 5 ) :365 - 370.
  • 4Stanley S, Franklin MD, Shehzad A, et al. Is pulse pressure useful in predicting risk for coronary heart diseas? The Framingham Heart Study[J ]. Circulation, 1999,100:354 - 360.
  • 5O' rourke M, Frohlich ED. Pulse pressure is this a clinically useful risk factor[J]? Hypertension, 1999,34:372 - 374.
  • 6蒋雄京,李臣文.大动脉硬化-临床医师面临新的挑战[J].高血压杂志,1999,7(3):198-200. 被引量:41
  • 7王宏宇,张维忠,龚兰生,李志明,邱慧丽,范明昌,吴美枝.高血压病大动脉扩张性与左室肥厚关系的探讨[J].中华心血管病杂志,2000,28(3):177-180. 被引量:115
  • 8张素华.2型糖尿病与冠心病[J].辽宁实用糖尿病杂志,2001,9(4):1-4. 被引量:21

共引文献29

同被引文献73

引证文献7

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部